Skip to main content

Monday, July 20, 2026

🇺🇸 Americas FDA
🇪🇺 Europe EMA
🌏 Asia-Pacific NMPA

Intelligence
Breaking Signal
All Latest Intelligence FDA actions, trial readouts, deals — updated continuously

Browse All Topics 216 topic hubs A–Z — approvals, trials, regulatory
Drug Approvals New FDA/EMA decisions & label changes
Clinical Readouts Phase data, trial updates, congress signals
M&A & Licensing Deals, partnerships, asset transfers
Press Releases Company announcements & product launches
Regulatory Watch
Regulatory Intelligence Agency actions, submission types, compliance context

FDA (US) US regulatory actions & guidance
EMA (Europe) CHMP opinions, EPAR updates
APAC Regulators PMDA, NMPA, CDSCO coverage
Market Access Pricing, HTA, reimbursement decisions
Industry Pulse
Manufacturing & Supply Capacity, supply chain, CDMO activity

Digital Health AI, diagnostics, and health technology
Executive Analysis Analyst commentary & deep takes
Supplier Hub CRO, CDMO, reagents & lab partners
CDMO Directory Contract manufacturing partners
CRO Directory Clinical research & bioanalytical CROs
Live Live signal
4 breaking stories in Americas

FDA actions, trial readouts, and market-moving deals — updated continuously.

Drug approvals Event calendar

Editorial picks

Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Cardinal Health RBC
Markets
Regional Command Centers
Global Markets Overview US, EU, APAC — equal prominence, regulator context

United States FDA market · largest pharma economy
Europe EMA market · pricing & HTA dynamics
Asia-Pacific PMDA/NMPA · fastest-growing biotech
Market Dynamics
Market Access & Pricing Reimbursement, HTA decisions, launch strategy

Manufacturing Intel Capacity, supply, CDMO moves
Supplier Hub Life-science vendors & manufacturing partners
Regional News Feed Top stories in Americas
Commercial Strategy Go-to-market & audience reach
Congress & Calendar
Pharma Events Calendar Major congresses with editorial preview coverage

US Events ASCO, ASH, BIO — US calendar
EU Events ESMO, ECCO — European congresses
APAC Events JSMO, CSCO — Asia-Pacific
Upcoming (30 days) Next major events on the calendar
Market brief
Americas · FDA

Next major event: Cardinal Health RBC

Open Americas hub Global overview

Editorial picks

Cardinal Health RBC
Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Companies
Company Intelligence
Company Directory Pharma & biotech profiles with pipeline links

M&A & Licensing Acquisition & licensing activity
Press Releases Corporate announcements
Drug Approvals Approval news linked to companies
CRO Directory Clinical research organization partners
Pipeline & IP
Pipeline Programs R&D programs from ClinicalTrials.gov

Patents Landscape US pharma patents (A61K/A61P)
Phase III Programs Late-stage assets nearing approval
NDA / BLA Filings Regulatory submissions in flight
CDMO Directory Contract development & manufacturing vendors
Watchlist
Popular Companies Most-tracked pharma & biotech profiles

Pfizer
Johnson & Johnson
Roche
Novartis
Company signal
Track Pfizer & peers

Directory profiles linked to pipeline programs, patents, and deal coverage.

Pfizer profile Phase III programs

Editorial picks

Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Cardinal Health RBC
Drugs & Trials
Drug Intelligence
Drug Profiles INN profiles, regulatory status, competitive landscape

FDA Approved US-approved medicines
EMA Approved EU-approved medicines
Pipeline Assets Investigational compounds
Oncology Hub Anticancer & immuno-oncology therapies
Therapeutic Areas
Browse by Therapy Curated hubs with mechanism & target context

Obesity & Metabolic GLP-1, GIP/GLP-1, diabetes
Neurology & CNS Alzheimer's, MS, epilepsy
Rare Disease Orphan & gene therapies
Immunology Autoimmune biologics
Clinical Development
Clinical Trial Database Trials by stage, therapy, region — linked to pipeline

Phase III Pivotal trials & readouts
Phase II Proof-of-concept signals
Trial Phases Guide Reference for trial design
Patents IP expiry & competitive moats
Asset watch
Keytruda (pembrolizumab)

INN profiles, regulatory status, linked trials, and competitive landscape.

Drug profile Trial database

Editorial picks

Oncology hub
Obesity & metabolic hub
Research & Tools
Analysis & Commentary
Analyst Intelligence Expert commentary on approvals, trials, and strategy

Regulatory Analysis Agency policy deep-dives
Clinical Analysis Trial design & readout takes
M&A Commentary Deal structure & valuation
Data Sources Methodology & provenance
ICH Guidelines Regulatory reference library
Reports & Whitepapers
Whitepaper Library Downloadable reports — FDA, EMA, APAC coverage

Featured Reports Editor's picks
US (FDA) Reports US regulatory intelligence
EU (EMA) Reports European market briefs
APAC Reports Asia-Pacific coverage
Professional Tools
Pharma Tools Suite Calculators, QA/QC, regulatory reference — free

Calculators Dosage, dilution, clearance
QA/QC Suite GMP, stability, risk tools
Lab Tools Buffer, molarity, dilution calculators
Supplier Hub Lab reagents, equipment & QA/QC vendors
Life Science Reagents Fluorescent dyes, antibodies, and kits
Free tools
GMP Checklist Generator

Audit-ready checklists plus calculators, QA/QC tools, and analyst reports.

Launch tool Featured reports

Editorial picks

Eli Lilly's Foundayo (Orforglipron) Receives FDA Approval for Obesity Treatment as Company Reports Strong Q1 2026 Results
Cardinal Health RBC

🇺🇸 Americas

Intelligence

View all intelligence →

Live 4 breaking stories in Americas

Drug approvals Event calendar

Breaking Signal

All Latest Intelligence

Browse All Topics
Drug Approvals
Clinical Readouts
M&A & Licensing
Press Releases

Regulatory Watch

Regulatory Intelligence

FDA (US)
EMA (Europe)
APAC Regulators
Market Access

Industry Pulse

Manufacturing & Supply

Digital Health
Executive Analysis
Supplier Hub
CDMO Directory
CRO Directory

Markets

View all markets →

Americas · FDA

Open Americas hub Global overview

Regional Command Centers

Global Markets Overview

United States
Europe
Asia-Pacific

Market Dynamics

Market Access & Pricing

Manufacturing Intel
Supplier Hub
Regional News Feed
Commercial Strategy

Congress & Calendar

Pharma Events Calendar

US Events
EU Events
APAC Events
Upcoming (30 days)

Companies

View all companies →

Track Pfizer & peers

Pfizer profile Phase III programs

Company Intelligence

Company Directory

M&A & Licensing
Press Releases
Drug Approvals
CRO Directory

Pipeline & IP

Pipeline Programs

Patents Landscape
Phase III Programs
NDA / BLA Filings
CDMO Directory

Watchlist

Popular Companies

Pfizer
Johnson & Johnson
Roche
Novartis

Drugs & Trials

View all drugs & trials →

Keytruda (pembrolizumab)

Drug profile Trial database

Drug Intelligence

Drug Profiles

FDA Approved
EMA Approved
Pipeline Assets
Oncology Hub

Therapeutic Areas

Browse by Therapy

Obesity & Metabolic
Neurology & CNS
Rare Disease
Immunology

Clinical Development

Clinical Trial Database

Phase III
Phase II
Trial Phases Guide
Patents

Research & Tools

View all research & tools →

GMP Checklist Generator

Launch tool Featured reports

Analysis & Commentary

Analyst Intelligence

Regulatory Analysis
Clinical Analysis
M&A Commentary
Data Sources
ICH Guidelines

Reports & Whitepapers

Whitepaper Library

Featured Reports
US (FDA) Reports
EU (EMA) Reports
APAC Reports

Professional Tools

Pharma Tools Suite

Calculators
QA/QC Suite
Lab Tools
Supplier Hub
Life Science Reagents

Choose your region

🇺🇸 Americas FDA 🇪🇺 Europe EMA 🌏 Asia-Pacific NMPA

ESC

Global intelligence search — drugs, companies, trials, events 🇺🇸 FDA articles only

Trending Now

Conference Cardinal Health RBC Jul 22 event
Conference 2026 TPA Conference Jul 24 event
Top drug Keytruda (pembrolizumab) drug
Top drug Ozempic / Wegovy (semaglutide) drug
Approval Valbenazine NEUROCRINE BIOSCIENCES pipeline
Approval Iloperidone Vanda Pharmaceuticals Netherlands pipeline
Company Pfizer company
Company Johnson & Johnson company

Explore Entities

Drugs 4.2K INN profiles & regulatory status Companies 800 Sponsor & marketer profiles Patents 1.6K US & EP patent intelligence Pipelines 335 Clinical development programs Trials 335 Stage & therapy intelligence Events 134 Congress & regulatory meetings

Continue Researching

Therapeutic Areas

Oncology Obesity Neurology & CNS Rare disease Immunology & autoimmune

Regulatory Intelligence

FDA Approvals EMA Updates NMPA Updates Fast Track Orphan Drug

Press Enter for full results · ↑↓ to navigate

🇺🇸 FDA

Home/Events/Dermatology Events

Dermatology Events

0 events

No events found for this filter.

We use cookies to enhance your experience, analyze traffic, and for marketing. By continuing to use our site, you consent to our use of cookies. Privacy Policy

News & Intelligence

Latest News
Drug Approvals
Clinical Trials
Pipeline Programs
Regulatory News
M&A & Licensing
Market Intelligence

Companies

Pharma Companies
Biotech Companies
CRO Directory
CDMO Directory
Company Rankings
Funding Activity
Press Releases

Drugs & Diseases

Drug Profiles
Disease Hubs
Oncology Drugs
Obesity & Metabolic
Cardiovascular
Rare Diseases
Neurology
Immunology

Research & Data

Clinical Trial Database
Patents
Publications & Analysis
Your Watchlist
Whitepapers
Biomarkers & Targets
Data Sources

Events

Event Calendar
US Events
Europe Events
APAC Events
Major Conferences
Upcoming Events

Company

About NovaPharmaNews
Editorial Team
Editorial Policy
Methodology & Data
Contact
Careers
Media Kit
Partnerships
Nexvora Platform

Explore the intelligence graph

Topic Clusters

Diseases

Oncology
Diabetes & Metabolic
Obesity
Cardiovascular
Rare Disease
Neurology
Immunology
Infectious Disease
Respiratory
Dermatology

Therapeutic Areas

Cell Therapy
Gene Therapy
RNA Therapeutics
Antibody Therapies
Vaccines
Precision Medicine

Regulatory

Regulatory Hub
FDA
EMA
MHRA
PMDA
CDSCO & NMPA

Market Intelligence

Global Markets
Market Access (US)
Manufacturing
Funding Rounds
IPO Activity
Venture Capital
Partnerships
Licensing Activity

Entity and authority graph navigation

Popular Pharma Companies

United Therapeutics Europe
Takeda
BRIGHT MINDS BIOSCIENCES
BioMarin Pharmaceutical Australia
Jazz Pharmaceuticals Ireland
Anaxis Pharma
BridgeBio Oncology Therapeutics
Teva Pharma
Karyopharm Therapeutics
NEUROCRINE BIOSCIENCES
Regeneron UK
Tonix Pharmaceuticals Holding
Vanda Pharmaceuticals Netherlands
Ultragenyx UK
Acadia Pharmaceuticals
IONIS PHARMACEUTICALS
GSK Glaxo Smith
HOFFMANN-LA ROCHE
NovoThirteen
Nektar Therapeutics UK

Regulatory Agencies

FDA (US)
EMA (Europe)
MHRA (UK)
PMDA (Japan)
CDSCO (India)

Popular Drugs

ABACAVIR SULFATE (abacavir sulfate)
ABIRATERONE KRKA (abiraterone acetate)
ACAMPROSATE CALCIUM (acamprosate calcium)
ACEBUTOLOL HYDROCHLORIDE (acebutolol hydrochloride)
VIZZ (aceclidine hydrochloride)
ACEPHEN (acetaminophen)
DIAMOX (acetazolamide)
ACETAZOLAMIDE SODIUM (acetazolamide sodium)
DYMELOR (acetohexamide)
ACETYLCYSTEINE (acetylcysteine)

Trending Diseases

Oncology Hub
Obesity Hub
Rare Disease Hub
Neurology Hub
Autoimmune Hub
FDA Approved

Regional Editions

🇺🇸 Americas
🇪🇺 Europe
🌏 Asia-Pacific
🌐 Global Markets

YouTube
X
Reddit
Quora
LinkedIn

Powered by Nexvora — AI-powered pharmaceutical intelligence infrastructure

Privacy
Terms
Cookies
Sitemap

Nexvora LLC · 30 N Gould St, STE R, Sheridan, WY 82801, USA

The information provided is for healthcare professional reference only and does not constitute medical advice, diagnosis, or treatment recommendation. Always consult qualified healthcare providers.